No Data
Guobang Pharma Unit's Florfenicol Production Passes US FDA Inspection
Guobang Pharmaceutical (605507.SH): Subsidiary product florfenicol has passed the USA FDA on-site inspection.
On December 19, Gelonghui reported that Guobang Pharmaceutical (605507.SH) announced that its wholly-owned subsidiary ShanDong Guobang Pharmaceutical Co., Ltd. (hereinafter referred to as 'ShanDong Guobang') underwent a cGMP (current Good Manufacturing Practice) on-site inspection by the USA Food and Drug Administration (FDA) from September 23 to September 27, 2024. The scope of the inspection covered six major systems: quality system, materials, production, packaging and labeling, facilities and equipment, and laboratory control. Recently, ShanDong Guobang received the on-site inspection report (EIR) issued by the USA FDA.
Guobang Pharmaceutical (605507.SH) has repurchased 1.11% of its shares cumulatively, spending approximately 0.101 billion yuan.
Guobang Pharmaceutical (605507.SH) issued an announcement. As of November 30, 2024, the company has completed the centralized competitive bidding process...
Guobang Pharmaceutical (605507.SH): Zhejiang Min Investment Henghua and Silk Road Fund have cumulatively reduced their shareholding by 2.56%.
On November 29, Gelonghui reported that Guobang Pharmaceutical (605507.SH) announced that on November 29, 2024, it received a "Notice of Shareholding Reduction Results" issued by Zhejiang Min Investment Henghua and Silk Road Fund. As of November 29, 2024, Zhejiang Min Investment Henghua and Silk Road Fund have collectively reduced their shareholding by 14,303,883 shares, accounting for 2.56% of the company's total equity, and this shareholding reduction plan has been completed.
Private Companies Are Guobang Pharma Ltd.'s (SHSE:605507) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥608m Last Week
Pacific Securities: Q3 revenue and profit growth of the active pharmaceutical ingredient sector have accelerated significantly, bullish on the high growth trend in Q4 performance.
In Q1 2024, the gross margin of the sector was 36.38%, with a net margin of 12.78%. In Q2, the gross margin was 37.21%, with a net margin of 15.52%. In Q3, the gross margin was 38.27%, +1.88pct year-on-year, +1.06pct quarter-on-quarter, with a net margin of 14.07%, +3.98pct year-on-year, -1.45pct quarter-on-quarter, both gross margin and net margin reaching a new high compared to the same period in the past three years.
Guobang Pharma Ltd.'s (SHSE:605507) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
